Technical Analysis for SER - Serina Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 8.80 | -3.51% | -0.32 |
SER closed down 2.87 percent on Wednesday, May 8, 2024, on 17 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | -3.51% | |
| Narrow Range Bar | Range Contraction | -3.51% | |
| Inside Day | Range Contraction | -3.51% | |
| Wide Bands | Range Expansion | -3.51% | |
| Gapped Down | Weakness | -3.51% | |
| Oversold Stochastic | Weakness | -3.51% | |
| Wide Bands | Range Expansion | -6.28% | |
| Gapped Up | Strength | -6.28% | |
| Oversold Stochastic | Weakness | -6.28% | |
| Narrow Range Bar | Range Contraction | 4.02% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 2 hours ago |
| 2x Volume Pace | about 2 hours ago |
| 1.5x Volume Pace | about 2 hours ago |
| 3x Volume Pace | about 2 hours ago |
| Outside Day | about 2 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Serina is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina’s POZ PlatformTM delivery technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (“PEG”) and other biocompatible polymers. Serina’s POZ PlatformTM partners are at the forefront in advancing LNP delivery technology to develop novel RNA therapeutics.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Molecular Biology Polymers RNA Pegylation Neurological Diseases Rna Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Molecular Biology Polymers RNA Pegylation Neurological Diseases Rna Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.7143 |
| 52 Week Low | 8.1001 |
| Average Volume | 5,055 |
| 200-Day Moving Average | 18.31 |
| 50-Day Moving Average | 12.21 |
| 20-Day Moving Average | 10.11 |
| 10-Day Moving Average | 9.15 |
| Average True Range | 0.85 |
| RSI (14) | 36.71 |
| ADX | 45.19 |
| +DI | 20.46 |
| -DI | 42.25 |
| Chandelier Exit (Long, 3 ATRs) | 10.25 |
| Chandelier Exit (Short, 3 ATRs) | 10.66 |
| Upper Bollinger Bands | 12.35 |
| Lower Bollinger Band | 7.88 |
| Percent B (%b) | 0.28 |
| BandWidth | 44.12 |
| MACD Line | -0.98 |
| MACD Signal Line | -0.98 |
| MACD Histogram | 0.0014 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.12 | ||||
| Resistance 3 (R3) | 9.12 | 9.12 | 9.12 | ||
| Resistance 2 (R2) | 9.12 | 9.12 | 9.12 | 9.12 | |
| Resistance 1 (R1) | 9.12 | 9.12 | 9.12 | 9.12 | 9.12 |
| Pivot Point | 9.12 | 9.12 | 9.12 | 9.12 | 9.12 |
| Support 1 (S1) | 9.12 | 9.12 | 9.12 | 9.12 | 9.12 |
| Support 2 (S2) | 9.12 | 9.12 | 9.12 | 9.12 | |
| Support 3 (S3) | 9.12 | 9.12 | 9.12 | ||
| Support 4 (S4) | 9.12 |
